7133-90-6Relevant articles and documents
Internal rotation and intramolecular hydrogen bonding in thiosalicylamide: gas phase electron diffraction study supported by quantum chemical calculations
Kolesnikova, Inna N.,Rykov, Anatolii N.,Shuvalov, Maxim V.,Shishkov, Igor F.
, p. 1993 - 2001 (2019)
The molecular structure of thiosalicylamide (2-hydroxythiobenzamide) was investigated in the gas phase at 401?K by means of gas electron diffraction (GED) combined with quantum chemical (QC) calculations. Special attention was paid to the internal rotation of the thioamide group. Structural refinement was performed taking into account rovibrational corrections to the thermal-average internuclear distances calculated with harmonic and anharmonic (cubic) MP2/cc-pVTZ force constants in terms of static and dynamic models. It was shown that both models fitted the GED data equally well. The results of the GED refinement revealed that in the equilibrium structure, the thioamide group is twisted by about 30° with respect to the phenol ring plane. This is the result of an interatomic repulsion of hydrogen atom in the amide group from the closest hydrogen atom of the benzene ring, which overcomes the energy gain from the π?π conjugation of the thioamide group and the aromatic system of thiosalicylamide. Natural bond orbital (NBO) analysis and comparison of the thiosalicylamide molecular structure with those of related compounds revealed hydrogen-bonded fragment between the hydroxyl and thiocarbonyl groups. The structure of thiosalicylamide in the gas phase was found to be markedly different from that in the solid phase due to the effect of intermolecular hydrogen bonding in the crystal.
METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE
-
Paragraph 0027; 00165; 00174, (2020/02/14)
A method of modulating ribonucleotide reductase activity in a neoplastic cell includes administering to the cell an amount of a hydrazone or hydrazine ribonucleotide reductase modulator (RRmod), the amount being effective to inhibit neoplastic cell growth.
Structure-guided design of anti-cancer ribonucleotide reductase inhibitors
Misko, Tessianna A.,Liu, Yi-Ting,Harris, Michael E.,Oleinick, Nancy L.,Pink, John,Lee, Hsueh-Yun,Dealwis, Chris G.
, p. 438 - 450 (2019/01/14)
Ribonucleotide reductase (RR) catalyses the rate-limiting step of dNTP synthesis, establishing it as an important cancer target. While RR is traditionally inhibited by nucleoside-based antimetabolites, we recently discovered a naphthyl salicyl acyl hydrazone-based inhibitor (NSAH) that binds reversibly to the catalytic site (C-site). Here we report the synthesis and in vitro evaluation of 13 distinct compounds (TP1-13) with improved binding to hRR over NSAH (TP8), with lower KD’s and more predicted residue interactions. Moreover, TP6 displayed the greatest growth inhibiting effect in the Panc1 pancreatic cancer cell line with an IC50 of 0.393 μM. This represents more than a 2-fold improvement over NSAH, making TP6 the most potent compound against pancreatic cancer emerging from the hydrazone inhibitors. NSAH was optimised by the addition of cyclic and polar groups replacing the naphthyl moiety, which occupies the phosphate-binding pocket in the C-site, establishing a new direction in inhibitor design.